Published in J Clin Oncol on February 01, 2006
Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray". Eur J Nucl Med Mol Imaging (2007) 1.71
Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies. J Nucl Med (2010) 1.45
Clinical radioimmunotherapy--the role of radiobiology. Nat Rev Clin Oncol (2011) 1.10
Cancer radioimmunotherapy. Immunotherapy (2011) 1.10
Have we overestimated the benefit of human(ized) antibodies? MAbs (2010) 1.05
Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. Cancer Biother Radiopharm (2013) 1.05
Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv Drug Deliv Rev (2008) 1.00
Consolidation for ovarian cancer in remission. J Clin Oncol (2006) 0.97
Radioimmunotherapy of solid tumors: searching for the right target. Curr Drug Deliv (2011) 0.96
Natural and Induced Humoral Responses to MUC1. Cancers (Basel) (2011) 0.93
Repeated Intraperitoneal alpha-Radioimmunotherapy of Ovarian Cancer in Mice. J Oncol (2009) 0.92
Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis. J Nucl Med (2009) 0.91
The potential and hurdles of targeted alpha therapy - clinical trials and beyond. Front Oncol (2014) 0.90
The MUC1 Ectodomain: A Novel and Efficient Target for Gold Nanoparticle Clustering and Vapor Nanobubble Generation. Theranostics (2012) 0.88
Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb. PLoS One (2013) 0.87
Emerging trends for radioimmunotherapy in solid tumors. Cancer Biother Radiopharm (2013) 0.86
Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer. Expert Opin Drug Deliv (2014) 0.85
Transmembrane mucins as novel therapeutic targets. Expert Rev Endocrinol Metab (2011) 0.82
Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis. Cancer (2010) 0.82
Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis. Front Med (Lausanne) (2015) 0.78
Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Immunotherapy (2011) 0.78
Monoclonal antibodies in gynecological cancer: a critical point of view. Clin Dev Immunol (2011) 0.78
Application of (212)Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation. AIMS Med Sci (2015) 0.78
Not so "SMART". J Clin Oncol (2006) 0.76
GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. Clin Transl Oncol (2013) 0.76
Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model. EJNMMI Res (2014) 0.76
Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential. Sci Rep (2016) 0.76
Radiolabelled monoclonal antibodies in the treatment of metastatic cancer. Curr Oncol (2007) 0.75
Ovarian cancer (advanced). BMJ Clin Evid (2009) 0.75
Therapeutic targets and new directions for antibodies developed for ovarian cancer. MAbs (2016) 0.75
Pre-operative evaluation of circulating KL-6 levels as a biomarker for epithelial ovarian carcinoma and its correlation with tumor MUC1 expression. Oncol Lett (2017) 0.75
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell (2007) 6.44
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol (2009) 4.11
Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol (2005) 3.31
Gene-targeted mice lacking the Trex1 (DNase III) 3'-->5' DNA exonuclease develop inflammatory myocarditis. Mol Cell Biol (2004) 3.19
The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell (2012) 3.10
RalGDS is required for tumor formation in a model of skin carcinogenesis. Cancer Cell (2005) 3.09
CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells (2009) 2.76
Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res (2002) 2.71
MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer (2009) 2.45
Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol (2005) 2.42
Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res (2002) 2.38
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Gene-targeted mice lacking the Ung uracil-DNA glycosylase develop B-cell lymphomas. Oncogene (2003) 2.02
Putative direct and indirect Wnt targets identified through consistent gene expression changes in APC-mutant intestinal adenomas from humans and mice. Hum Mol Genet (2008) 2.00
Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol Oncol (2006) 1.96
Requirement for interaction of PI3-kinase p110α with RAS in lung tumor maintenance. Cancer Cell (2013) 1.95
Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res (2011) 1.90
Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther (2006) 1.88
Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res (2006) 1.84
Severe polyposis in Apc(1322T) mice is associated with submaximal Wnt signalling and increased expression of the stem cell marker Lgr5. Gut (2010) 1.84
Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol (2006) 1.75
Time-domain fluorescence lifetime imaging applied to biological tissue. Photochem Photobiol Sci (2004) 1.75
Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol (2003) 1.68
Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene (2002) 1.67
Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res (2003) 1.64
Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med (2012) 1.62
E-cadherin/catenin complex status in solid pseudopapillary tumor of the pancreas. Am J Surg Pathol (2008) 1.60
Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. J Clin Oncol (2003) 1.60
Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol (2010) 1.60
RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell (2013) 1.60
Murine but not human mesenchymal stem cells generate osteosarcoma-like lesions in the lung. Stem Cells (2007) 1.59
HELQ promotes RAD51 paralogue-dependent repair to avert germ cell loss and tumorigenesis. Nature (2013) 1.57
Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. BMC Med Genomics (2009) 1.55
Mechanisms of Cables 1 gene inactivation in human ovarian cancer development. Cancer Biol Ther (2007) 1.54
Cancer antigen 125 level after a bilateral salpingo-oophorectomy: what is the contribution of the ovary to the cancer antigen 125 level? Menopause (2011) 1.48
MicroRNA involvement in glioblastoma pathogenesis. Biochem Biophys Res Commun (2009) 1.45
Ovarian status in healthy postmenopausal women: follow-up 12 months after transvaginal ultrasound. Menopause (2009) 1.42
The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol (2006) 1.41
L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst (2013) 1.40
Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J Exp Clin Cancer Res (2010) 1.36
Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med (2012) 1.34
Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther (2004) 1.34
Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res (2007) 1.34
Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol (2004) 1.33
SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation. Clin Cancer Res (2006) 1.32
BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis. Gynecol Oncol (2003) 1.31
The Apc 1322T mouse develops severe polyposis associated with submaximal nuclear beta-catenin expression. Gastroenterology (2009) 1.28
MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci (2011) 1.28
Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer (2012) 1.26
A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 1.25
Genetic polymorphisms and microRNAs: new direction in molecular epidemiology of solid cancer. J Cell Mol Med (2012) 1.24
CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells. Cancer Chemother Pharmacol (2008) 1.23
Early postnatal death and motor disorders in mice congenitally deficient in calnexin expression. Mol Cell Biol (2002) 1.22
L1 and HERV-W retrotransposons are hypomethylated in human ovarian carcinomas. Mol Cancer (2004) 1.20
Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs (2010) 1.20
Myh deficiency enhances intestinal tumorigenesis in multiple intestinal neoplasia (ApcMin/+) mice. Cancer Res (2004) 1.19
MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol (2012) 1.16
Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis. Proteomics (2010) 1.16
Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. PLoS One (2009) 1.15
Laughter: the best medicine? Oncologist (2005) 1.15
Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res (2003) 1.15
Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. J Transl Med (2008) 1.15
Genetic deletion of RALA and RALB small GTPases reveals redundant functions in development and tumorigenesis. Curr Biol (2012) 1.15
Evaluation of SNPs in miR-196-a2, miR-27a and miR-146a as risk factors of colorectal cancer. World J Gastroenterol (2012) 1.14
Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. Cancer Chemother Pharmacol (2004) 1.14
Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. J Pathol (2012) 1.14
Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas. PLoS One (2007) 1.13
Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol (2005) 1.13
Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J Pathol (2013) 1.12
Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin Cancer Res (2008) 1.12
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med (2010) 1.12
MiR-34b is associated with clinical outcome in triple-negative breast cancer patients. Diagn Pathol (2012) 1.11
Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol (2013) 1.10
Antibody GD3G7 selected against embryonic glycosaminoglycans defines chondroitin sulfate-E domains highly up-regulated in ovarian cancer and involved in vascular endothelial growth factor binding. Am J Pathol (2007) 1.10
Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer (2002) 1.09
MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma. Tumour Biol (2012) 1.08
Stomach development is dependent on fibroblast growth factor 10/fibroblast growth factor receptor 2b-mediated signaling. Gastroenterology (2006) 1.08
FLIM FRET technology for drug discovery: automated multiwell-plate high-content analysis, multiplexed readouts and application in situ. Chemphyschem (2011) 1.08
Serine proteases HTRA1 and HTRA3 are down-regulated with increasing grades of human endometrial cancer. Gynecol Oncol (2006) 1.07
Predictors of clinical outcomes in the laparoscopic management of adnexal masses. Obstet Gynecol (2003) 1.06
Correlation of CXCL12 expression and FoxP3+ cell infiltration with human papillomavirus infection and clinicopathological progression of cervical cancer. Am J Pathol (2009) 1.06
Retroperitoneal myolipoma. World J Surg Oncol (2005) 1.05
Selective removal of ovarian cancer cells from human ascites fluid using magnetic nanoparticles. Nanomedicine (2009) 1.05
Expression profiling in progressive stages of fumarate-hydratase deficiency: the contribution of metabolic changes to tumorigenesis. Cancer Res (2010) 1.05
Tissue eosinophilia: a morphologic marker for assessing stromal invasion in laryngeal squamous neoplasms. BMC Clin Pathol (2005) 1.04
Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int J Cancer (2007) 1.04
Functional analyses of the cancer stem cell-like properties of human endometrial tumor initiating cells. Cell Cycle (2007) 1.04
The heparan sulfate motif (GlcNS6S-IdoA2S)3, common in heparin, has a strict topography and is involved in cell behavior and disease. J Biol Chem (2010) 1.03
GBP1 overexpression is associated with a paclitaxel resistance phenotype. Cancer Chemother Pharmacol (2005) 1.03
Evidence for the complexity of microRNA-mediated regulation in ovarian cancer: a systems approach. PLoS One (2011) 1.02
MicroRNAs and glioblastoma: roles in core signalling pathways and potential clinical implications. J Cell Mol Med (2011) 1.02
Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecol Oncol (2005) 1.02
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci U S A (2006) 1.02
Concordant F-18 FDG PET and Y-90 Bremsstrahlung scans depict selective delivery of Y-90-microspheres to liver tumors: confirmation with histopathology. Clin Nucl Med (2007) 1.01
Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma. J Transl Med (2007) 1.01
Trophoblastic disease. Int J Gynaecol Obstet (2012) 1.01
8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol Pharmacol (2007) 1.00